Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Epizyme price target raised to $36 from $25 at H.C. Wainwright » 07:14
02/25/20
02/25
07:14
02/25/20
07:14
EPZM

Epizyme

$21.65 /

-3.24 (-13.02%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Yesterday
On The Fly
Fly Intel: Wall Street's top stories for Monday » 17:14
02/24/20
02/24
17:14
02/24/20
17:14
AAPL

Apple

$298.16 /

-14.86 (-4.75%)

, NKE

Nike

$95.90 /

-4.34 (-4.33%)

, UNH

UnitedHealth

$277.84 /

-23.415 (-7.77%)

, BRK.A

Berkshire Hathaway

$333,007.50 /

-10742.5 (-3.13%)

, BRK.B

Berkshire Hathaway

$221.60 /

-7.645 (-3.33%)

, DAL

Delta Air Lines

$54.24 /

-3.63 (-6.27%)

, AAL

American Airlines

$25.45 /

-2.38 (-8.55%)

, UAL

United Airlines

$75.46 /

-2.56 (-3.28%)

, JBLU

JetBlue

$19.39 /

-1.23 (-5.97%)

, LUV

Southwest

$54.09 /

-2.44 (-4.32%)

, GILD

Gilead

$72.95 /

+3.25 (+4.66%)

, INTU

Intuit

$286.50 /

-11.27 (-3.78%)

, MNK

Mallinckrodt

$4.20 /

-0.925 (-18.05%)

, TEVA

Teva

$12.70 /

-0.49 (-3.71%)

, ENDP

Endo

$6.02 /

-0.065 (-1.07%)

, MYL

Mylan

$20.33 /

-0.83 (-3.92%)

, CAH

Cardinal Health

$58.14 /

-1.58 (-2.65%)

, ABC

AmerisourceBergen

$94.91 /

-2.08 (-2.14%)

, MCK

McKesson

$165.55 /

-5.42 (-3.17%)

, UTHR

United Therapeutics

$115.29 /

+8.33 (+7.79%)

, VHC

VirnetX

$5.63 /

+0.63 (+12.60%)

, WIFI

Boingo Wireless

$14.32 /

-0.13 (-0.90%)

, EPZM

Epizyme

$21.65 /

-3.24 (-13.02%)

Stocks in the U.S. and in…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:36
02/24/20
02/24
12:36
02/24/20
12:36
UNH

UnitedHealth

$278.79 /

-22.465 (-7.46%)

, AAPL

Apple

$299.15 /

-13.87 (-4.43%)

, NKE

Nike

$96.11 /

-4.13 (-4.12%)

, GILD

Gilead

$72.41 /

+2.71 (+3.89%)

, BRK.A

Berkshire Hathaway

$334,500.00 /

-9250 (-2.69%)

, DAL

Delta Air Lines

$53.61 /

-4.26 (-7.36%)

, AAL

American Airlines

$25.13 /

-2.7 (-9.70%)

, JBLU

JetBlue

$19.28 /

-1.34 (-6.50%)

, LUV

Southwest

$53.95 /

-2.58 (-4.56%)

, UAL

United Airlines

$74.99 /

-3.03 (-3.88%)

, INTU

Intuit

$286.06 /

-11.71 (-3.93%)

, NGM

NGM Biopharmaceuticals

$19.45 /

+3.45 (+21.56%)

, VHC

VirnetX

$5.45 /

+0.45 (+9.00%)

, KOS

Kosmos

$4.25 /

-0.72 (-14.50%)

, EPZM

Epizyme

$21.00 /

-3.89 (-15.63%)

Stocks have been sharply…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies » 08:39
02/24/20
02/24
08:39
02/24/20
08:39
EPZM

Epizyme

$24.89 /

-0.64 (-2.51%)

, BPMC

Blueprint Medicines

$67.71 /

-0.17 (-0.25%)

, DCPH

Deciphera

$55.05 /

-0.74 (-1.33%)

, MTRX

Matrix Service

$14.71 /

-0.05 (-0.34%)

, IMMU

Immunomedics

$18.09 /

+0.07 (+0.39%)

, KPTI

Karyopharm

$16.06 /

-0.35 (-2.13%)

, AGIO

Agios Pharmaceuticals

$53.00 /

-0.73 (-1.36%)

Jefferies analysts…

Jefferies analysts Michael Yee and Andrew Tsai noted that of the 66 standalone small-to-mid cap companies with an approved oncology drug in the last decade, 22 of those, or 61%, were ultimately acquired. Within that context, they noted that Epizyme (EPZM), Blueprint Medicines (BPMC), Deciphera (DCPH), Matrix Service (MRTX) and Immunomedics (IMMU) are some of the oncology companies that continue to fit the M&A criteria they examined. The analysts also noted that the M&A rate is over 55% for standalone oncology SMIDs with an approved oral, small molecule, adding that it is possible Epizyme, Blueprint, Karyopharm (KPTI) and Agios Pharmaceuticals (AGIO) could be attractive M&A candidates since they have maintained sole U.S. rights. Yee and Tsai additionally noted that with 22 cancer IPOs in 2019 that the M&A "pool is being replenished."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Epizyme sees cash runway extending 'into at least 2022' » 06:33
02/24/20
02/24
06:33
02/24/20
06:33
EPZM

Epizyme

$24.89 /

-0.64 (-2.51%)

Based on its current…

Based on its current operating plans, Epizyme expects its current cash runway to extend into at least 2022. Additionally, the company expects its GAAP operating expenses for 2020 to be between $300M-$330M inclusive of the milestones due to Eisai for the FDA approval of TAVERIK for epithelioid sarcoma and for follicular lymphoma, if approved.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Epizyme reports Q4 EPS (59c), consensus (50c) » 06:32
02/24/20
02/24
06:32
02/24/20
06:32
EPZM

Epizyme

$24.89 /

-0.64 (-2.51%)

Reports Q4 collaboration…

Reports Q4 collaboration revenue $4.3M, consensus $3.08M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Hot Stocks
Fly Intel: Pre-market Movers » 09:16
02/14/20
02/14
09:16
02/14/20
09:16
NVDA

Nvidia

$270.81 /

-1.75 (-0.64%)

, CGC

Canopy Growth

$19.52 /

-0.11 (-0.56%)

, AXL

American Axle

$10.20 /

-0.15 (-1.45%)

, ROKU

Roku

$139.06 /

+0.82 (+0.59%)

, EPZM

Epizyme

$22.23 /

-0.48 (-2.11%)

, EBAY

eBay

$37.18 /

+0.04 (+0.11%)

, CARG

CarGurus

$34.09 /

-0.36 (-1.04%)

, YELP

Yelp

$36.47 /

+1.12 (+3.17%)

, ANET

Arista Networks

$238.14 /

+3.74 (+1.60%)

, YNDX

Yandex

$48.60 /

+0.05 (+0.10%)

, PINS

Pinterest

$23.58 /

-0.34 (-1.42%)

UP AFTER EARNINGS: Nvidia…

UP AFTER EARNINGS: Nvidia (NVDA), up 6%... Canopy Growth (CGC), up 24%... American Axle (AXL), up 1%... Roku (ROKU), up 8%. ALSO HIGHER: Epizyme (EPZM), up 3% after announcing that the FDA has accepted for filing the company's new drug application for the accelerated approval of Tazverik for patients with relapsed or refractory follicular lymphoma who have received at least two prior lines of systemic therapy... eBay (EBAY), up 2% after completing the sale of StubHub to viagogo for $4.05B in cash and announcing plans to buy back more stock. DOWN AFTER EARNINGS: CarGurus (CARG), down 20%... Yelp (YELP), down 9%... Arista Networks (ANET), down 8%... Yandex (YNDX), down 3%. ALSO LOWER: Pinterest (PINS), down 2% after The Information reported just before yesterday's market close that an experimental group within Facebook (FB) has released a Pinterest-like app for saving and sharing photos.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Epizyme: FDA accepts for filing NDA for accelerated approval of TAZVERIK » 06:44
02/14/20
02/14
06:44
02/14/20
06:44
EPZM

Epizyme

$22.23 /

-0.48 (-2.11%)

Epizyme announced that…

Epizyme announced that the U.S. FDA has accepted for filing the company's New Drug Application for the accelerated approval of TAZVERIK for patients with relapsed or refractory follicular lymphoma who have received at least two prior lines of systemic therapy. The FDA granted Priority Review and has designated the company's application as a supplemental NDA with a Prescription Drug User Fee Act target action date of June 18, 2020. Priority Review is granted to investigational therapies that, if approved, may offer significant improvements in the treatment, prevention or diagnosis of a serious condition.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Epizyme strength attributed to NCCN recommendation » 12:07
02/10/20
02/10
12:07
02/10/20
12:07
EPZM

Epizyme

$22.20 /

+0.81 (+3.79%)

Trading contacts tell The…

Trading contacts tell The Fly that strength in shares of Epizyme is related to a recommendation related to the company's tazemetostat drug being issued by the National Comprehensive Cancer Network, or NCCN. Information about the NCCN's treatment guidelines is only available to users with a site login. Near midday, shares of Epizyme are up 99c, or 4.6%, to $22.34. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Hot Stocks
Fly Intel: Pre-market Movers » 09:02
01/24/20
01/24
09:02
01/24/20
09:02
AVGO

Broadcom

$319.73 /

+6.81 (+2.18%)

, AAPL

Apple

$319.27 /

+1.42 (+0.45%)

, INTC

Intel

$63.32 /

+0.53 (+0.84%)

, CYOU

Changyou.com

$9.92 /

+0.06 (+0.61%)

, SOHU

Sohu.com

$11.25 /

+0.07 (+0.63%)

, AXP

American Express

$131.40 /

-0.16 (-0.12%)

, TEAM

Atlassian

$132.89 /

+1.52 (+1.16%)

, SYF

Synchrony

$36.19 /

-0.23 (-0.63%)

, SNV

Synovus

$39.43 /

+0.2 (+0.51%)

, ERIC

Ericsson

$8.98 /

+0.015 (+0.17%)

, DFS

Discover

$85.77 /

+0.405 (+0.47%)

, EPZM

Epizyme

$26.72 /

+1.165 (+4.56%)

HIGHER: Changyou.com…

HIGHER: Changyou.com (CYOU), up 8% after entering into a merger agreement with Sohu Game, an indirectly wholly-owned subsidiary of Sohu.com (SOHU). The company will be acquired by the Sohu Group in an all-cash transaction implying an equity value of the company of approximately $579M... Broadcom (AVGO), up 3% after announcing that certain of its subsidiaries have entered into two separate multi-year statement of work agreements with Apple (AAPL). Both are for the supply of a range of specified high-performance wireless components and modules to Apple for use in its products. UP AFTER EARNINGS: American Express (AXP), up 2%... Intel (INTC), up 4%... Atlassian (TEAM), up 8%. DOWN AFTER EARNINGS: Synchrony (SYF), down 5%... Synovus (SNV), down 1%... Ericsson (ERIC), down 7%... Discover (DFS), down 7%. ALSO LOWER: Epizyme (EPZM), down 4% after SVB Leerink analyst Andrew Berens downgraded shares to Market Perform from Outperform with a price target of $18, up from $16, following the approval of Tazverik in epithelioid sarcoma. In a research note to investors, Berens says he believes the approval was widely anticipated by the market following the unanimous FDA advisory committee vote and that the tangible fundamental opportunities for the drug are fully baked-in.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.